Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Short Maintenance Trial in advanced urothelial cancer
NL-OMON59993Phase 4Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of avelumab in transitional cell carcinoma (TCC) and bladder cancer (2 arms), sponsored by Erasmus MC. Primary endpoint: 18-month overall survival. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
avelumab
03
Conditions
transitional cell carcinoma (TCC)bladder cancer
Beyond the preview
Go deeper on NL-OMON59993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59993.